A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

NCT01975831 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Ovarian Cancer
Colorectal Cancer
Cervical Cancer
Renal Cell Carcinoma

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]
[object Object]